IPP Bureau
NADMED brings first CE-marked NAD+ analysis kit to the market
By IPP Bureau - June 30, 2022
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
India’s first mRNA vaccine from Gennova gets DCGI approval
By IPP Bureau - June 30, 2022
It is a two dose vaccine to be administered intramuscularly at 28 days apart
TTK Healthcare launches e-Superstore - 'Love Depot'
By IPP Bureau - June 30, 2022
LoveDepot.com addresses this gap that is yawning in the market
Experts call for “Disability Inclusive Health Care System” to address health inequity
By IPP Bureau - June 30, 2022
We must try to make the health care system more accessible for people with disabilities
Weizmann’s study sheds new light on a promising antidepressant
By IPP Bureau - June 30, 2022
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
MTPA announces long-term findings from post-marketing safety study of Radicava
By IPP Bureau - June 30, 2022
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine
By IPP Bureau - June 30, 2022
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
By IPP Bureau - June 30, 2022
The settlement and dismissal resolves all claims between the parties
Glenmark Pharmaceuticals expand its OTC portfolio
By IPP Bureau - June 29, 2022
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
By IPP Bureau - June 29, 2022
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
By IPP Bureau - June 29, 2022
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
DTx Pharma appoints Peter Condon as Chief Business Officer
By IPP Bureau - June 29, 2022
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Govt calls upon states to step up vigil against Covid
By IPP Bureau - June 29, 2022
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
Apollo Education UK launches the Apollo International Clinical Fellowship Programme
By IPP Bureau - June 29, 2022
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
Wacker to build biotechnology center in Munich
By IPP Bureau - June 28, 2022
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
